Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRAF | P15056 | 11/20 | 0.63 |
| ▸ | TLR8 | Q9NR97 | 1/20 | 0.60 |
| ▸ | CSNK1D | P48730 | 1/20 | 0.58 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.55 |
| ▸ | NPC1 | O15118 | 3/20 | 0.55 |
| ▸ | RAB9A | P51151 | 3/20 | 0.55 |
| ▸ | MAP2K1 | Q02750 | 1/20 | 0.52 |
| ▸ | CLK4 | Q9HAZ1 | 1/20 | 0.52 |
| ▸ | DYRK1B | Q9Y463 | 1/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.51 |
| ▸ | HPGD | P15428 | 2/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.51 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.51 |
| ▸ | TP53 | P04637 | 1/20 | 0.50 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.50 |
| ▸ | STAT1 | P42224 | 1/20 | 0.50 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.50 |
| ▸ | RELA | Q04206 | 1/20 | 0.50 |
| ▸ | MAPK13 | O15264 | 1/20 | 0.49 |
| ▸ | LIMK1 | P53667 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3155668 | 0.89 | TLR8 (0.72) | BRAFTLR8KDM4ENPC1RAB9A | |
| SCHEMBL11472378 | 0.87 | MAP2K1 (0.65) | BRAFKDM4ENPC1RAB9AMAP2K1 | |
| SCHEMBL3164329 | 0.85 | BRAF (0.82) | BRAFTLR8KDM4EALDH1A1HPGD | |
| SCHEMBL4656785 | 0.84 | BRAF (0.59) | BRAFTLR8KDM4ENPC1RAB9A | |
| SCHEMBL3169712 | 0.84 | BRAF (0.61) | BRAFTLR8KDM4ENPC1RAB9A | |
| SCHEMBL3161762 | 0.84 | BRAF (0.58) | BRAFTLR8KDM4ENPC1RAB9A | |
| SCHEMBL11351081 | 0.82 | BRAF (0.58) | BRAFTLR8CSNK1DKDM4ENPC1 | |
| SCHEMBL3161975 | 0.81 | MARK2 (0.62) | BRAFTLR8KDM4ENPC1RAB9A | |
| SCHEMBL3170569 | 0.81 | BRAF (0.61) | BRAFTLR8KDM4ENPC1RAB9A | |
| SCHEMBL4763004 | 0.81 | BRAF (0.80) | BRAFMAPK13LIMK1MARK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1996594-A2 | PYRAZOLO[1,5-A]PYRIMIDINE DERIVATIVES AND METHODS OF USE THEREOF | Wyeth a Corporation of the State of Delaware (US) | 2008-12-03 | — | — | EP | disclosed |
| WO-2007109093-A2 | PYRAZOLO[1,5-A]PYRIMIDINE DERIVATIVES AND METHODS OF USE THEREOF | WYETH (US) | 2007-09-27 | — | — | WO | disclosed |
| US-20070219183-A1 | Dihydropyrazolo[1,5-A]pyrimidine and dihydroimidazo[1,5-A]pyrimidine derivatives and methods of use thereof | WYETH (US) | 2007-09-20 | — | — | US | disclosed |
| US-20070219186-A1 | Pyrazolo[1,5-A]pyrimidine derivatives and methods of use thereof | WYETH (US) | 2007-09-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070219186-A1 | Pyrazolo[1,5-A]pyrimidine derivatives and methods of use thereof | DPYD, TYMP, TYMS | BRAF 289/4885TLR8 3604/4885CSNK1D 2378/4885 |
| US-20070219183-A1 | Dihydropyrazolo[1,5-A]pyrimidine and dihydroimidazo[1,5-A]pyrimidine derivatives and methods of use thereof | DPYD, DUT, TYMP | BRAF 817/4885TLR8 3100/4885CSNK1D 2602/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.